By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022
Other Corporate Information
Stockholm, Sweden – Xbrane Biopharma AB (publ) (Nasdaq Stockholm: XBRANE), invites analysts, investors and the media to its Capital Markets Day on September 22, 2022 by reason of EMA's positive opinion for ranibizumab biosimilar candidate Ximluci® (Xlucane®) and the now imminent launch in Europe.
The Capital Markets Day will be held in the Nils Ringertz hall, Biomedicum, floor 3, Solnavägen 9, Solna, starting at 2 pm and will also be broadcast digitally. Refreshments are served from 1.30 pm.
Please register your personal participation at: IR@xbrane.com and digital participation by following the link: https://tv.streamfabriken.com/xbrane-biopharma-cmd-2022.